Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 7 | 5 | 12 |
| 1997 | 2 | 1 | 3 |
| 1998 | 8 | 2 | 10 |
| 1999 | 1 | 0 | 1 |
| 2000 | 9 | 0 | 9 |
| 2001 | 1 | 4 | 5 |
| 2002 | 7 | 2 | 9 |
| 2003 | 4 | 2 | 6 |
| 2004 | 4 | 4 | 8 |
| 2005 | 4 | 1 | 5 |
| 2006 | 13 | 1 | 14 |
| 2007 | 7 | 0 | 7 |
| 2008 | 4 | 3 | 7 |
| 2009 | 8 | 6 | 14 |
| 2010 | 6 | 2 | 8 |
| 2011 | 2 | 0 | 2 |
| 2012 | 5 | 2 | 7 |
| 2013 | 5 | 3 | 8 |
| 2014 | 5 | 1 | 6 |
| 2015 | 4 | 2 | 6 |
| 2016 | 3 | 0 | 3 |
| 2018 | 5 | 0 | 5 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Development of an LC-MS/MS Method for Measurement of Irinotecan and Its Major Metabolites in Plasma: Technical Considerations. Lab Med. 2022 Jan 06; 53(1):47-52.
-
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. Br J Haematol. 2021 11; 195(3):e138-e141.
-
Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
-
Synergetic Inhibition of Human Colorectal Cancer Cells by Combining Polyyne-Enriched Fraction from Oplopanax elatus and Irinotecan. Nutr Cancer. 2019; 71(3):472-482.
-
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479.
-
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Mol Carcinog. 2018 12; 57(12):1751-1762.
-
Quality assessment of Penthorum chinense Pursh through multicomponent qualification and fingerprint, chemometric, and antihepatocarcinoma analyses. Food Funct. 2018 Jul 17; 9(7):3807-3814.
-
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
-
GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 10 01; 380(2):384-392.
-
Drug-Coated Balloon Venoplasty for In-Stent Restenosis in a Patient With Recurrent Pulmonary Vein Stenosis Post Ablation for Atrial Fibrillation: Initial Experience With a New Treatment Technique. J Invasive Cardiol. 2016 May; 28(5):E44-8.